Report cover image

Global Obstetrics and Gynecology Drugs Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published May 17, 2025
Length 195 Pages
SKU # APRC20361327

Description

Summary

According to APO Research, The global Obstetrics and Gynecology Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Obstetrics and Gynecology Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Obstetrics and Gynecology Drugs include Abbott, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Bayer and Amgen, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Obstetrics and Gynecology Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Obstetrics and Gynecology Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Obstetrics and Gynecology Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Obstetrics and Gynecology Drugs revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Obstetrics and Gynecology Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Obstetrics and Gynecology Drugs revenue, projected growth trends, production technology, application and end-user industry.

Obstetrics and Gynecology Drugs Segment by Company

Abbott
Johnson & Johnson
Novartis
Merck
Roche
Eli Lilly
Pfizer
Bayer
Amgen
Abbvie
AstraZeneca
TherapeuticsMD
Lupin
GlaxoSmithKline
Ferring
Obstetrics and Gynecology Drugs Segment by Type

Hormonal Therapy
Non-Hormonal Therapy
Obstetrics and Gynecology Drugs Segment by Application

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Obstetrics and Gynecology Drugs Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Obstetrics and Gynecology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Obstetrics and Gynecology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Obstetrics and Gynecology Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Obstetrics and Gynecology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Obstetrics and Gynecology Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Obstetrics and Gynecology Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Obstetrics and Gynecology Drugs Market by Type
1.2.1 Global Obstetrics and Gynecology Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Hormonal Therapy
1.2.3 Non-Hormonal Therapy
1.3 Obstetrics and Gynecology Drugs Market by Application
1.3.1 Global Obstetrics and Gynecology Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacies
1.3.3 Online Pharmacies
1.3.4 Retail Pharmacies
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Obstetrics and Gynecology Drugs Market Dynamics
2.1 Obstetrics and Gynecology Drugs Industry Trends
2.2 Obstetrics and Gynecology Drugs Industry Drivers
2.3 Obstetrics and Gynecology Drugs Industry Opportunities and Challenges
2.4 Obstetrics and Gynecology Drugs Industry Restraints
3 Global Growth Perspective
3.1 Global Obstetrics and Gynecology Drugs Market Perspective (2020-2031)
3.2 Global Obstetrics and Gynecology Drugs Growth Trends by Region
3.2.1 Global Obstetrics and Gynecology Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Obstetrics and Gynecology Drugs Market Size by Region (2020-2025)
3.2.3 Global Obstetrics and Gynecology Drugs Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Obstetrics and Gynecology Drugs Revenue by Players
4.1.1 Global Obstetrics and Gynecology Drugs Revenue by Players (2020-2025)
4.1.2 Global Obstetrics and Gynecology Drugs Revenue Market Share by Players (2020-2025)
4.1.3 Global Obstetrics and Gynecology Drugs Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Obstetrics and Gynecology Drugs Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Obstetrics and Gynecology Drugs Key Players Headquarters & Area Served
4.4 Global Obstetrics and Gynecology Drugs Players, Product Type & Application
4.5 Global Obstetrics and Gynecology Drugs Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Obstetrics and Gynecology Drugs Market CR5 and HHI
4.6.3 2024 Obstetrics and Gynecology Drugs Tier 1, Tier 2, and Tier 3
5 Obstetrics and Gynecology Drugs Market Size by Type
5.1 Global Obstetrics and Gynecology Drugs Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Obstetrics and Gynecology Drugs Revenue by Type (2020-2031)
5.3 Global Obstetrics and Gynecology Drugs Revenue Market Share by Type (2020-2031)
6 Obstetrics and Gynecology Drugs Market Size by Application
6.1 Global Obstetrics and Gynecology Drugs Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Obstetrics and Gynecology Drugs Revenue by Application (2020-2031)
6.3 Global Obstetrics and Gynecology Drugs Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Abbott
7.1.1 Abbott Comapny Information
7.1.2 Abbott Business Overview
7.1.3 Abbott Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.1.4 Abbott Obstetrics and Gynecology Drugs Product Portfolio
7.1.5 Abbott Recent Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Comapny Information
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.2.4 Johnson & Johnson Obstetrics and Gynecology Drugs Product Portfolio
7.2.5 Johnson & Johnson Recent Developments
7.3 Novartis
7.3.1 Novartis Comapny Information
7.3.2 Novartis Business Overview
7.3.3 Novartis Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.3.4 Novartis Obstetrics and Gynecology Drugs Product Portfolio
7.3.5 Novartis Recent Developments
7.4 Merck
7.4.1 Merck Comapny Information
7.4.2 Merck Business Overview
7.4.3 Merck Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.4.4 Merck Obstetrics and Gynecology Drugs Product Portfolio
7.4.5 Merck Recent Developments
7.5 Roche
7.5.1 Roche Comapny Information
7.5.2 Roche Business Overview
7.5.3 Roche Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.5.4 Roche Obstetrics and Gynecology Drugs Product Portfolio
7.5.5 Roche Recent Developments
7.6 Eli Lilly
7.6.1 Eli Lilly Comapny Information
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.6.4 Eli Lilly Obstetrics and Gynecology Drugs Product Portfolio
7.6.5 Eli Lilly Recent Developments
7.7 Pfizer
7.7.1 Pfizer Comapny Information
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.7.4 Pfizer Obstetrics and Gynecology Drugs Product Portfolio
7.7.5 Pfizer Recent Developments
7.8 Bayer
7.8.1 Bayer Comapny Information
7.8.2 Bayer Business Overview
7.8.3 Bayer Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.8.4 Bayer Obstetrics and Gynecology Drugs Product Portfolio
7.8.5 Bayer Recent Developments
7.9 Amgen
7.9.1 Amgen Comapny Information
7.9.2 Amgen Business Overview
7.9.3 Amgen Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.9.4 Amgen Obstetrics and Gynecology Drugs Product Portfolio
7.9.5 Amgen Recent Developments
7.10 Abbvie
7.10.1 Abbvie Comapny Information
7.10.2 Abbvie Business Overview
7.10.3 Abbvie Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.10.4 Abbvie Obstetrics and Gynecology Drugs Product Portfolio
7.10.5 Abbvie Recent Developments
7.11 AstraZeneca
7.11.1 AstraZeneca Comapny Information
7.11.2 AstraZeneca Business Overview
7.11.3 AstraZeneca Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.11.4 AstraZeneca Obstetrics and Gynecology Drugs Product Portfolio
7.11.5 AstraZeneca Recent Developments
7.12 TherapeuticsMD
7.12.1 TherapeuticsMD Comapny Information
7.12.2 TherapeuticsMD Business Overview
7.12.3 TherapeuticsMD Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.12.4 TherapeuticsMD Obstetrics and Gynecology Drugs Product Portfolio
7.12.5 TherapeuticsMD Recent Developments
7.13 Lupin
7.13.1 Lupin Comapny Information
7.13.2 Lupin Business Overview
7.13.3 Lupin Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.13.4 Lupin Obstetrics and Gynecology Drugs Product Portfolio
7.13.5 Lupin Recent Developments
7.14 GlaxoSmithKline
7.14.1 GlaxoSmithKline Comapny Information
7.14.2 GlaxoSmithKline Business Overview
7.14.3 GlaxoSmithKline Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.14.4 GlaxoSmithKline Obstetrics and Gynecology Drugs Product Portfolio
7.14.5 GlaxoSmithKline Recent Developments
7.15 Ferring
7.15.1 Ferring Comapny Information
7.15.2 Ferring Business Overview
7.15.3 Ferring Obstetrics and Gynecology Drugs Revenue and Gross Margin (2020-2025)
7.15.4 Ferring Obstetrics and Gynecology Drugs Product Portfolio
7.15.5 Ferring Recent Developments
8 North America
8.1 North America Obstetrics and Gynecology Drugs Revenue (2020-2031)
8.2 North America Obstetrics and Gynecology Drugs Revenue by Type (2020-2031)
8.2.1 North America Obstetrics and Gynecology Drugs Revenue by Type (2020-2025)
8.2.2 North America Obstetrics and Gynecology Drugs Revenue by Type (2026-2031)
8.3 North America Obstetrics and Gynecology Drugs Revenue Share by Type (2020-2031)
8.4 North America Obstetrics and Gynecology Drugs Revenue by Application (2020-2031)
8.4.1 North America Obstetrics and Gynecology Drugs Revenue by Application (2020-2025)
8.4.2 North America Obstetrics and Gynecology Drugs Revenue by Application (2026-2031)
8.5 North America Obstetrics and Gynecology Drugs Revenue Share by Application (2020-2031)
8.6 North America Obstetrics and Gynecology Drugs Revenue by Country
8.6.1 North America Obstetrics and Gynecology Drugs Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Obstetrics and Gynecology Drugs Revenue by Country (2020-2025)
8.6.3 North America Obstetrics and Gynecology Drugs Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Obstetrics and Gynecology Drugs Revenue (2020-2031)
9.2 Europe Obstetrics and Gynecology Drugs Revenue by Type (2020-2031)
9.2.1 Europe Obstetrics and Gynecology Drugs Revenue by Type (2020-2025)
9.2.2 Europe Obstetrics and Gynecology Drugs Revenue by Type (2026-2031)
9.3 Europe Obstetrics and Gynecology Drugs Revenue Share by Type (2020-2031)
9.4 Europe Obstetrics and Gynecology Drugs Revenue by Application (2020-2031)
9.4.1 Europe Obstetrics and Gynecology Drugs Revenue by Application (2020-2025)
9.4.2 Europe Obstetrics and Gynecology Drugs Revenue by Application (2026-2031)
9.5 Europe Obstetrics and Gynecology Drugs Revenue Share by Application (2020-2031)
9.6 Europe Obstetrics and Gynecology Drugs Revenue by Country
9.6.1 Europe Obstetrics and Gynecology Drugs Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Obstetrics and Gynecology Drugs Revenue by Country (2020-2025)
9.6.3 Europe Obstetrics and Gynecology Drugs Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
10 China
10.1 China Obstetrics and Gynecology Drugs Revenue (2020-2031)
10.2 China Obstetrics and Gynecology Drugs Revenue by Type (2020-2031)
10.2.1 China Obstetrics and Gynecology Drugs Revenue by Type (2020-2025)
10.2.2 China Obstetrics and Gynecology Drugs Revenue by Type (2026-2031)
10.3 China Obstetrics and Gynecology Drugs Revenue Share by Type (2020-2031)
10.4 China Obstetrics and Gynecology Drugs Revenue by Application (2020-2031)
10.4.1 China Obstetrics and Gynecology Drugs Revenue by Application (2020-2025)
10.4.2 China Obstetrics and Gynecology Drugs Revenue by Application (2026-2031)
10.5 China Obstetrics and Gynecology Drugs Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Obstetrics and Gynecology Drugs Revenue (2020-2031)
11.2 Asia Obstetrics and Gynecology Drugs Revenue by Type (2020-2031)
11.2.1 Asia Obstetrics and Gynecology Drugs Revenue by Type (2020-2025)
11.2.2 Asia Obstetrics and Gynecology Drugs Revenue by Type (2026-2031)
11.3 Asia Obstetrics and Gynecology Drugs Revenue Share by Type (2020-2031)
11.4 Asia Obstetrics and Gynecology Drugs Revenue by Application (2020-2031)
11.4.1 Asia Obstetrics and Gynecology Drugs Revenue by Application (2020-2025)
11.4.2 Asia Obstetrics and Gynecology Drugs Revenue by Application (2026-2031)
11.5 Asia Obstetrics and Gynecology Drugs Revenue Share by Application (2020-2031)
11.6 Asia Obstetrics and Gynecology Drugs Revenue by Country
11.6.1 Asia Obstetrics and Gynecology Drugs Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Obstetrics and Gynecology Drugs Revenue by Country (2020-2025)
11.6.3 Asia Obstetrics and Gynecology Drugs Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Obstetrics and Gynecology Drugs Revenue (2020-2031)
12.2 SAMEA Obstetrics and Gynecology Drugs Revenue by Type (2020-2031)
12.2.1 SAMEA Obstetrics and Gynecology Drugs Revenue by Type (2020-2025)
12.2.2 SAMEA Obstetrics and Gynecology Drugs Revenue by Type (2026-2031)
12.3 SAMEA Obstetrics and Gynecology Drugs Revenue Share by Type (2020-2031)
12.4 SAMEA Obstetrics and Gynecology Drugs Revenue by Application (2020-2031)
12.4.1 SAMEA Obstetrics and Gynecology Drugs Revenue by Application (2020-2025)
12.4.2 SAMEA Obstetrics and Gynecology Drugs Revenue by Application (2026-2031)
12.5 SAMEA Obstetrics and Gynecology Drugs Revenue Share by Application (2020-2031)
12.6 SAMEA Obstetrics and Gynecology Drugs Revenue by Country
12.6.1 SAMEA Obstetrics and Gynecology Drugs Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Obstetrics and Gynecology Drugs Revenue by Country (2020-2025)
12.6.3 SAMEA Obstetrics and Gynecology Drugs Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.